Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma - PubMed
4 hours ago
- #oncology
- #cholangiocarcinoma
- #clinical trial
- Neoadjuvant GOLP regimen (gemcitabine-oxaliplatin, lenvatinib, and anti-PD1 antibody) tested in resectable high-risk intrahepatic cholangiocarcinoma.
- Phase 2-3 trial compared neoadjuvant GOLP followed by surgery vs. surgery alone (control), with adjuvant capecitabine in both groups.
- Primary endpoint: event-free survival (EFS) significantly longer in neoadjuvant group (18.0 months) vs. control (8.7 months).
- 24-month overall survival was 79% (neoadjuvant) vs. 61% (control), but did not meet predefined significance threshold.
- Adverse events occurred in 97% of neoadjuvant patients (28% grade ≥3) vs. 70% in control, with no treatment-related deaths.
- Conclusion: Neoadjuvant GOLP improves EFS with manageable toxicity in high-risk intrahepatic cholangiocarcinoma.